The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis

Abstract Objectives Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. Methods A systematic literature review of randomized controlled trials (RCTs) in RA com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2021-12, Vol.61 (1), p.76-89
Hauptverfasser: McWilliams, Daniel F, Thankaraj, Divya, Jones-Diette, Julie, Morgan, Rheinallt, Ifesemen, Onosi S, Shenker, Nicholas G, Walsh, David A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 89
container_issue 1
container_start_page 76
container_title Rheumatology (Oxford, England)
container_volume 61
creator McWilliams, Daniel F
Thankaraj, Divya
Jones-Diette, Julie
Morgan, Rheinallt
Ifesemen, Onosi S
Shenker, Nicholas G
Walsh, David A
description Abstract Objectives Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. Methods A systematic literature review of randomized controlled trials (RCTs) in RA comparing systemic GCs to inactive treatment. Three databases were and spontaneous pain and evoked pain outcomes were extracted. Standardized mean differences (SMDs) and mean differences were meta-analysed. Heterogeneity (I2, tau statistics) and bias (funnel plot, Egger’s test) were assessed. Subgroup analyses investigated sources of variation. This study was pre-registered (PROSPERO CRD42019111562). Results A total of 18 903 titles, 880 abstracts and 226 full texts were assessed. Thirty-three RCTs suitable for the meta-analysis included 3123 participants. Pain scores (spontaneous pain) decreased in participants treated with oral GCs; SMD = −0.65 (15 studies, 95% CI −0.82, −0.49, P 3–6 months and −7 mm (95% CI −13, 0) at >6 months. Similar findings were obtained when evoked pain outcomes were examined. Data from five RCTs suggested improvement also in fatigue during GC treatment. Conclusion Oral GCs are analgesic in RA. The benefit is greatest shortly after initiation and GCs might not achieve clinically important pain relief beyond 3 months. Treatments other than anti-inflammatory GCs should be considered to reduce the long-term burden of pain in RA.
doi_str_mv 10.1093/rheumatology/keab503
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8742830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keab503</oup_id><sourcerecordid>2548408266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3994-ad58d6c2129df112b525d3cf9ea3a2ceb146d07bef1e816a6dc7b6c65fe559d93</originalsourceid><addsrcrecordid>eNqNkU2LFDEQhoMo7rr6D0Ry9NJOPnu6PQiy-AULXtZzqE4qM9HuzpikV_rmTzcys8N6EwpSJO_7VIWXkJecveGsl5u0x2WCEse4Wzc_EAbN5CNyyVUrGialeHzuhbogz3L-zhjTXHZPyYVUgkst1CX5fbtHit4HC3al0dO85oJTsHQ3LjbamEqwsV6lGFymPiZ6gDDTWvcLBEchlX0KJeS3FE4EqD46hmqEsiSkCe8C_qIwOzphgQZmGNcc8nPyxMOY8cXpvCLfPn64vf7c3Hz99OX6_U1jZd-rBpzuXGsFF73znItBC-2k9T2CBGFxqH91bDug59jxFlpnt0NrW-1R69718oq8O3IPyzChsziXBKM5pDBBWk2EYP59mcPe7OKd6bZKdJJVwOsTIMWfC-ZippAtjiPMGJdshFadYp1o2ypVR6lNMeeE_jyGM_M3PPMwPHMKr9pePVzxbLpPqwo2R0FcDv-H_AOb8bFa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548408266</pqid></control><display><type>article</type><title>The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>McWilliams, Daniel F ; Thankaraj, Divya ; Jones-Diette, Julie ; Morgan, Rheinallt ; Ifesemen, Onosi S ; Shenker, Nicholas G ; Walsh, David A</creator><creatorcontrib>McWilliams, Daniel F ; Thankaraj, Divya ; Jones-Diette, Julie ; Morgan, Rheinallt ; Ifesemen, Onosi S ; Shenker, Nicholas G ; Walsh, David A</creatorcontrib><description>Abstract Objectives Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. Methods A systematic literature review of randomized controlled trials (RCTs) in RA comparing systemic GCs to inactive treatment. Three databases were and spontaneous pain and evoked pain outcomes were extracted. Standardized mean differences (SMDs) and mean differences were meta-analysed. Heterogeneity (I2, tau statistics) and bias (funnel plot, Egger’s test) were assessed. Subgroup analyses investigated sources of variation. This study was pre-registered (PROSPERO CRD42019111562). Results A total of 18 903 titles, 880 abstracts and 226 full texts were assessed. Thirty-three RCTs suitable for the meta-analysis included 3123 participants. Pain scores (spontaneous pain) decreased in participants treated with oral GCs; SMD = −0.65 (15 studies, 95% CI −0.82, −0.49, P &lt;0.001) with significant heterogeneity (I2 = 56%, P =0.0002). Efficacy displayed time-related decreases after GC initiation. Mean difference visual analogue scale pain was −15 mm (95% CI −20, −9) greater improvement in GC than control at ≤3 months, −8 mm (95% CI −12, −3) at &gt;3–6 months and −7 mm (95% CI −13, 0) at &gt;6 months. Similar findings were obtained when evoked pain outcomes were examined. Data from five RCTs suggested improvement also in fatigue during GC treatment. Conclusion Oral GCs are analgesic in RA. The benefit is greatest shortly after initiation and GCs might not achieve clinically important pain relief beyond 3 months. Treatments other than anti-inflammatory GCs should be considered to reduce the long-term burden of pain in RA.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab503</identifier><identifier>PMID: 34213524</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - drug therapy ; Fatigue ; Glucocorticoids - administration &amp; dosage ; Humans ; Pain - drug therapy ; Pain - etiology ; Systematic Review and Meta Analysis</subject><ispartof>Rheumatology (Oxford, England), 2021-12, Vol.61 (1), p.76-89</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3994-ad58d6c2129df112b525d3cf9ea3a2ceb146d07bef1e816a6dc7b6c65fe559d93</citedby><cites>FETCH-LOGICAL-c3994-ad58d6c2129df112b525d3cf9ea3a2ceb146d07bef1e816a6dc7b6c65fe559d93</cites><orcidid>0000-0002-0581-1895 ; 0000-0002-9852-5811</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34213524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McWilliams, Daniel F</creatorcontrib><creatorcontrib>Thankaraj, Divya</creatorcontrib><creatorcontrib>Jones-Diette, Julie</creatorcontrib><creatorcontrib>Morgan, Rheinallt</creatorcontrib><creatorcontrib>Ifesemen, Onosi S</creatorcontrib><creatorcontrib>Shenker, Nicholas G</creatorcontrib><creatorcontrib>Walsh, David A</creatorcontrib><title>The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract Objectives Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. Methods A systematic literature review of randomized controlled trials (RCTs) in RA comparing systemic GCs to inactive treatment. Three databases were and spontaneous pain and evoked pain outcomes were extracted. Standardized mean differences (SMDs) and mean differences were meta-analysed. Heterogeneity (I2, tau statistics) and bias (funnel plot, Egger’s test) were assessed. Subgroup analyses investigated sources of variation. This study was pre-registered (PROSPERO CRD42019111562). Results A total of 18 903 titles, 880 abstracts and 226 full texts were assessed. Thirty-three RCTs suitable for the meta-analysis included 3123 participants. Pain scores (spontaneous pain) decreased in participants treated with oral GCs; SMD = −0.65 (15 studies, 95% CI −0.82, −0.49, P &lt;0.001) with significant heterogeneity (I2 = 56%, P =0.0002). Efficacy displayed time-related decreases after GC initiation. Mean difference visual analogue scale pain was −15 mm (95% CI −20, −9) greater improvement in GC than control at ≤3 months, −8 mm (95% CI −12, −3) at &gt;3–6 months and −7 mm (95% CI −13, 0) at &gt;6 months. Similar findings were obtained when evoked pain outcomes were examined. Data from five RCTs suggested improvement also in fatigue during GC treatment. Conclusion Oral GCs are analgesic in RA. The benefit is greatest shortly after initiation and GCs might not achieve clinically important pain relief beyond 3 months. Treatments other than anti-inflammatory GCs should be considered to reduce the long-term burden of pain in RA.</description><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Fatigue</subject><subject>Glucocorticoids - administration &amp; dosage</subject><subject>Humans</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><subject>Systematic Review and Meta Analysis</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkU2LFDEQhoMo7rr6D0Ry9NJOPnu6PQiy-AULXtZzqE4qM9HuzpikV_rmTzcys8N6EwpSJO_7VIWXkJecveGsl5u0x2WCEse4Wzc_EAbN5CNyyVUrGialeHzuhbogz3L-zhjTXHZPyYVUgkst1CX5fbtHit4HC3al0dO85oJTsHQ3LjbamEqwsV6lGFymPiZ6gDDTWvcLBEchlX0KJeS3FE4EqD46hmqEsiSkCe8C_qIwOzphgQZmGNcc8nPyxMOY8cXpvCLfPn64vf7c3Hz99OX6_U1jZd-rBpzuXGsFF73znItBC-2k9T2CBGFxqH91bDug59jxFlpnt0NrW-1R69718oq8O3IPyzChsziXBKM5pDBBWk2EYP59mcPe7OKd6bZKdJJVwOsTIMWfC-ZippAtjiPMGJdshFadYp1o2ypVR6lNMeeE_jyGM_M3PPMwPHMKr9pePVzxbLpPqwo2R0FcDv-H_AOb8bFa</recordid><startdate>20211224</startdate><enddate>20211224</enddate><creator>McWilliams, Daniel F</creator><creator>Thankaraj, Divya</creator><creator>Jones-Diette, Julie</creator><creator>Morgan, Rheinallt</creator><creator>Ifesemen, Onosi S</creator><creator>Shenker, Nicholas G</creator><creator>Walsh, David A</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0581-1895</orcidid><orcidid>https://orcid.org/0000-0002-9852-5811</orcidid></search><sort><creationdate>20211224</creationdate><title>The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis</title><author>McWilliams, Daniel F ; Thankaraj, Divya ; Jones-Diette, Julie ; Morgan, Rheinallt ; Ifesemen, Onosi S ; Shenker, Nicholas G ; Walsh, David A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3994-ad58d6c2129df112b525d3cf9ea3a2ceb146d07bef1e816a6dc7b6c65fe559d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Fatigue</topic><topic>Glucocorticoids - administration &amp; dosage</topic><topic>Humans</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><topic>Systematic Review and Meta Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McWilliams, Daniel F</creatorcontrib><creatorcontrib>Thankaraj, Divya</creatorcontrib><creatorcontrib>Jones-Diette, Julie</creatorcontrib><creatorcontrib>Morgan, Rheinallt</creatorcontrib><creatorcontrib>Ifesemen, Onosi S</creatorcontrib><creatorcontrib>Shenker, Nicholas G</creatorcontrib><creatorcontrib>Walsh, David A</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McWilliams, Daniel F</au><au>Thankaraj, Divya</au><au>Jones-Diette, Julie</au><au>Morgan, Rheinallt</au><au>Ifesemen, Onosi S</au><au>Shenker, Nicholas G</au><au>Walsh, David A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2021-12-24</date><risdate>2021</risdate><volume>61</volume><issue>1</issue><spage>76</spage><epage>89</epage><pages>76-89</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract Objectives Glucocorticosteroids (GCs) are recommended to suppress inflammation in people with active RA. This systematic review and meta-analysis aimed to quantify the effects of systemic GCs on RA pain. Methods A systematic literature review of randomized controlled trials (RCTs) in RA comparing systemic GCs to inactive treatment. Three databases were and spontaneous pain and evoked pain outcomes were extracted. Standardized mean differences (SMDs) and mean differences were meta-analysed. Heterogeneity (I2, tau statistics) and bias (funnel plot, Egger’s test) were assessed. Subgroup analyses investigated sources of variation. This study was pre-registered (PROSPERO CRD42019111562). Results A total of 18 903 titles, 880 abstracts and 226 full texts were assessed. Thirty-three RCTs suitable for the meta-analysis included 3123 participants. Pain scores (spontaneous pain) decreased in participants treated with oral GCs; SMD = −0.65 (15 studies, 95% CI −0.82, −0.49, P &lt;0.001) with significant heterogeneity (I2 = 56%, P =0.0002). Efficacy displayed time-related decreases after GC initiation. Mean difference visual analogue scale pain was −15 mm (95% CI −20, −9) greater improvement in GC than control at ≤3 months, −8 mm (95% CI −12, −3) at &gt;3–6 months and −7 mm (95% CI −13, 0) at &gt;6 months. Similar findings were obtained when evoked pain outcomes were examined. Data from five RCTs suggested improvement also in fatigue during GC treatment. Conclusion Oral GCs are analgesic in RA. The benefit is greatest shortly after initiation and GCs might not achieve clinically important pain relief beyond 3 months. Treatments other than anti-inflammatory GCs should be considered to reduce the long-term burden of pain in RA.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34213524</pmid><doi>10.1093/rheumatology/keab503</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-0581-1895</orcidid><orcidid>https://orcid.org/0000-0002-9852-5811</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2021-12, Vol.61 (1), p.76-89
issn 1462-0324
1462-0332
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8742830
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - drug therapy
Fatigue
Glucocorticoids - administration & dosage
Humans
Pain - drug therapy
Pain - etiology
Systematic Review and Meta Analysis
title The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T22%3A38%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20of%20systemic%20glucocorticosteroids%20for%20pain%20in%20rheumatoid%20arthritis:%20a%20systematic%20literature%20review%20and%20meta-analysis&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=McWilliams,%20Daniel%20F&rft.date=2021-12-24&rft.volume=61&rft.issue=1&rft.spage=76&rft.epage=89&rft.pages=76-89&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab503&rft_dat=%3Cproquest_pubme%3E2548408266%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548408266&rft_id=info:pmid/34213524&rft_oup_id=10.1093/rheumatology/keab503&rfr_iscdi=true